What is the appropriate initiation regimen for hydroxychloroquine, including loading and maintenance dosing, baseline ophthalmologic and laboratory assessments, and monitoring recommendations?

How to Start Hydroxychloroquine

Initiate hydroxychloroquine at a dose of ≤5.0 mg/kg based on actual body weight (or ≤400 mg/day for severely obese patients), perform a baseline ophthalmologic examination within the first year, and correct any electrolyte abnormalities before starting therapy. 1, 2, 3

Dosing Strategy

Weight-Based Dosing

• Calculate the dose using actual body weight at ≤5.0 mg/kg/day to minimize retinopathy risk, which remains below 2% during the first 10 years at this dosage. 1
• For severely obese patients, cap the maximum dose at 400 mg/day regardless of weight to avoid excessive cumulative exposure. 2, 4
• The standard tablet contains 200 mg hydroxychloroquine sulfate (equivalent to 155 mg base), so typical dosing is 200-400 mg daily. 3

No Loading Dose Required

• Do not use a loading dose regimen for chronic rheumatologic or dermatologic conditions—the evidence for loading doses comes only from short-term COVID-19 treatment protocols and is not applicable to long-term autoimmune disease management. 5
• Standard maintenance dosing from day one is appropriate for rheumatic diseases. 1

Pre-Treatment Assessment

Baseline Ophthalmologic Examination

• Perform a comprehensive fundus examination within the first year of initiating therapy to exclude pre-existing maculopathy and establish a reference point for future comparisons. 2, 3, 4
• The baseline exam should include:
  • Best corrected distance visual acuity (BCVA) 3
  • Spectral-domain optical coherence tomography (SD-OCT) 2, 3, 4
  • Fundus autofluorescence (FAF) 4
  • Automated threshold visual field testing of the central 10 degrees (or 24 degrees for patients of Asian descent) 3, 4
• If any pre-existing macular disease is identified at baseline, add automated visual fields and SD-OCT to the initial work-up immediately. 2

Cardiac Screening

• Obtain a baseline ECG to assess for QT prolongation and conduction abnormalities before starting therapy. 3
• Correct any electrolyte imbalances (hypokalemia, hypomagnesemia) prior to initiating hydroxychloroquine to reduce arrhythmia risk. 3
• Avoid hydroxychloroquine in patients with:
  • Congenital or acquired QT prolongation 3
  • Cardiac disease (heart failure, recent myocardial infarction) 3
  • Bradycardia <50 bpm 3
  • History of ventricular arrhythmias 3
  • Concurrent use of other QT-prolonging medications 3

Laboratory Assessment

• Check baseline renal function (GFR/creatinine) as renal impairment is a major risk factor for retinopathy and requires earlier screening initiation. 2, 3
• Measure baseline liver function tests, particularly if the patient has any risk factors for hepatotoxicity (alcohol use, concurrent hepatotoxic medications, or undiagnosed porphyria cutanea tarda). 3

Contraindications to Screen For

• Known hypersensitivity to 4-aminoquinoline compounds is an absolute contraindication. 3
• Active psoriasis: Use with extreme caution as hydroxychloroquine may precipitate severe flare-ups; avoid unless benefit clearly outweighs risk. 3
• Porphyria: Avoid hydroxychloroquine as it may exacerbate the condition and cause severe hepatotoxicity in porphyria cutanea tarda. 3

Ongoing Monitoring Schedule

First Year Follow-Up

• At the one-year mark, verify that:
  • The baseline fundus examination was completed 2
  • The dose remains ≤5.0 mg/kg actual body weight 2
  • No new risk factors have emerged (renal disease, tamoxifen use, significant weight loss) 2
• No routine annual screening tests are required at one year unless a major risk factor has developed. 2

Annual Screening Initiation

• For patients without major risk factors, begin annual ophthalmologic screening after 5 years of continuous use with automated visual fields and SD-OCT. 2, 3, 4
• Initiate annual screening earlier than 5 years if any of the following risk factors are present:
  • Daily dose >5.0 mg/kg actual body weight 2, 3
  • Renal impairment (reduced GFR) 2, 3
  • Concurrent tamoxifen therapy 2, 3
  • Pre-existing macular disease 2
  • Older age at initiation 4

Cardiac Monitoring

• Monitor cardiac function as clinically indicated during therapy, particularly if symptoms of cardiac compromise develop (dyspnea, edema, palpitations). 3
• Discontinue hydroxychloroquine immediately if cardiotoxicity is suspected or demonstrated by tissue biopsy. 3

Critical Safety Considerations

Retinopathy Risk Profile

• The cumulative risk of retinopathy is <1% within the first 5 years, <2% up to 10 years, and rises to approximately 20% after 20 years of continuous use. 2
• Retinopathy is irreversible and may continue to progress even after drug discontinuation, making early detection through proper screening essential. 2, 3
• When detected early (before retinal pigment epithelium damage), progression after discontinuation is typically mild and central visual acuity can be preserved. 2

Patient Education

• Inform patients about the risk of irreversible retinal toxicity and the critical importance of adherence to screening schedules. 1, 6
• Advise patients to seek immediate medical attention if they develop:
  • Visual changes or disturbances 3
  • Skin blisters, severe rash, or mucosal lesions (Stevens-Johnson syndrome, TEN, DRESS, AGEP) 3
  • Cardiac symptoms (palpitations, syncope, dyspnea) 3
  • Signs of liver injury (fatigue, dark urine, jaundice) 3

Common Pitfalls to Avoid

• Do not dose based on ideal body weight for most patients—actual body weight is the correct metric, with the exception of severely obese patients who should be capped at 400 mg/day. 1, 2, 4
• Do not defer the baseline ophthalmologic examination—it must be completed within the first year to establish a reference and rule out contraindications. 2, 3
• Do not assume screening can wait 5 years for all patients—those with renal disease, tamoxifen use, or doses >5.0 mg/kg require immediate annual screening from year one. 2, 3
• Do not ignore borderline ophthalmologic findings—even subtle changes on 10-2 visual fields should prompt objective testing with SD-OCT or multifocal ERG. 6
• Do not continue hydroxychloroquine casually if toxicity is detected—the goal is to maintain safe use for as long as possible, but confirmed toxicity warrants serious consideration of discontinuation in consultation with the prescribing physician. 1